Last reviewed · How we verify

Budesonida Pulmictan® 200 µg

Reig Jofre Group · Phase 1 active Small molecule

Budesonida Pulmictan® 200 µg is a Small molecule drug developed by Reig Jofre Group. It is currently in Phase 1 development. Also known as: Budesonide 200 µg (reference product (A))..

At a glance

Generic nameBudesonida Pulmictan® 200 µg
Also known asBudesonide 200 µg (reference product (A)).
SponsorReig Jofre Group
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Budesonida Pulmictan® 200 µg

What is Budesonida Pulmictan® 200 µg?

Budesonida Pulmictan® 200 µg is a Small molecule drug developed by Reig Jofre Group.

Who makes Budesonida Pulmictan® 200 µg?

Budesonida Pulmictan® 200 µg is developed by Reig Jofre Group (see full Reig Jofre Group pipeline at /company/reig-jofre-group).

Is Budesonida Pulmictan® 200 µg also known as anything else?

Budesonida Pulmictan® 200 µg is also known as Budesonide 200 µg (reference product (A))..

What development phase is Budesonida Pulmictan® 200 µg in?

Budesonida Pulmictan® 200 µg is in Phase 1.

Related